These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19707333)

  • 21. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
    PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
    Lyu H; Yang XH; Edgerton SM; Thor AD; Wu X; He Z; Liu B
    Oncotarget; 2016 Jan; 7(3):2921-35. PubMed ID: 26621843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival.
    Das S; Sondarva G; Viswakarma N; Nair RS; Osipo C; Tzivion G; Rana B; Rana A
    J Biol Chem; 2015 Aug; 290(35):21705-12. PubMed ID: 26152725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and
    Collins DM; Conlon NT; Kannan S; Verma CS; Eli LD; Lalani AS; Crown J
    Cancers (Basel); 2019 May; 11(6):. PubMed ID: 31141894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac toxicity of ErbB2-targeted therapies: what do we know?
    Perez EA
    Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S114-20. PubMed ID: 18777950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.
    Xia W; Bacus S; Hegde P; Husain I; Strum J; Liu L; Paulazzo G; Lyass L; Trusk P; Hill J; Harris J; Spector NL
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7795-800. PubMed ID: 16682622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment.
    Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Friedecky D; Hajduch M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2010 Dec; 154(4):281-8. PubMed ID: 21293538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
    Jackson JG; St Clair P; Sliwkowski MX; Brattain MG
    Cancer Res; 2004 Apr; 64(7):2601-9. PubMed ID: 15059917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
    Zhang D; Pal A; Bornmann WG; Yamasaki F; Esteva FJ; Hortobagyi GN; Bartholomeusz C; Ueno NT
    Mol Cancer Ther; 2008 Jul; 7(7):1846-50. PubMed ID: 18644997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
    Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
    Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of resistance to HER family targeting antibodies.
    Kruser TJ; Wheeler DL
    Exp Cell Res; 2010 Apr; 316(7):1083-100. PubMed ID: 20064507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The EGF receptor family as therapeutic targets in breast cancer.
    Lemmon MA
    Breast Dis; 2003; 18():33-43. PubMed ID: 15687687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.
    Xia W; Bacus S; Husain I; Liu L; Zhao S; Liu Z; Moseley MA; Thompson JW; Chen FL; Koch KM; Spector NL
    Mol Cancer Ther; 2010 Feb; 9(2):292-9. PubMed ID: 20124457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
    Nahta R; Yuan LX; Du Y; Esteva FJ
    Mol Cancer Ther; 2007 Feb; 6(2):667-74. PubMed ID: 17308062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.
    Nagy P; Jenei A; Damjanovich S; Jovin TM; Szölôsi J
    Pathol Oncol Res; 1999; 5(4):255-71. PubMed ID: 10607920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.